Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dominion Energy Inc (D) vs Mesoblast Limited (MESO) Price & Performance

Dominion Energy IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Dominion Energy Inc vs Mesoblast Limited — how do they compare? Dominion Energy Inc trades at $71.4 (market cap $62.71B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Dominion Energy Inc is far larger — about 29.6× Mesoblast Limited's market cap, and Dominion Energy Inc pays a 3.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

DMESO
Market Cap
$62.71B$2.12B
Sector
UtilitiesTechnology
52-Week High
$71.32$20.96
52-Week Low
$56.55$10.96
Enterprise Value
$115.11B$2.13B
Dividend Yield
3.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dominion Energy Inc

Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.

The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dominion Energy Inc

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.

Read more on D

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO